Glucose/ROS dual-responsive mitochondria-targeting nanozyme microneedles remodel mitochondrial homeostasis to orchestrate immune metabolic reprogramming for diabetic foot ulcer healing
Regenerative Biomaterials · 22.01.2026 · 13
DOI: 10.1093/rb/rbag153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Regenerative Biomaterials, online erschienen am 21.07.2026. Verfasst von Qi Dong und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioengineering and Health, Wuhan Textile University, Wuhan 430073, PR China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Department of Education Scientific Research Program, Wuhan Textile University Special Fund Project.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Diabetic foot ulcers (DFUs) develop a persistent vicious loop featuring impaired mitochondrial activity and massive buildup of reactive oxygen species (ROS), accompanied by disordered immune responses; these combined pathological changes hinder the regeneration of damaged tissues. Therapeutic strategies that spatiotemporally target mitochondria to couple redox homeostasis restoration, immunometabolic reprogramming and tissue regeneration remain an unmet clinical need. Here we report a glucose/ROS dual-responsive microneedle patch incorporating mitochondria-targeting metal–phenolic nanozymes for DFU treatment. Tannic acid-cerium (TA-Ce) nano-catalysts possess strong catalytic capacities analogous to natural superoxide dismutase and catalase enzymes. These dual biomimetic functions clear excess ROS, stabilize mitochondrial physiological balance and drive macrophages to shift from pro-inflammatory M1-type toward anti-inflammatory M2 subtypes, which ultimately breaks sustained inflammatory feedback loops. Notably, the nanozyme functions dually as a therapeutic agent and a dynamic crosslinker through reversible boronate ester chemistry, allowing stable loading and microenvironment-responsive, on-demand release aligned with the pathological features of diabetic wounds. In a full-thickness diabetic rat wound model, the microneedle patch achieves 92.64% wound closure on Day 14, significantly outperforming commercial dressings. This work establishes a mitochondria-centered immunometabolic therapeutic strategy and provides a translatable platform for chronic wound regeneration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Bioengineering and Health, Wuhan Textile University, Wuhan 430073, PR China.
- Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan 430060, PR China.
- Hubei Integrative Technology and Innovation Center for Advanced Fiberous Materials, Wuhan 430073, PR China.
- Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, PR China.
Förderung
- Hubei Provincial Department of Education Scientific Research Program
- Wuhan Textile University Special Fund Project
Zitieren
APA
Dong, Q., Xiong, S., Shu, B., Cai, Z., Wang, S., Ming, Y., Dong, X., Chen, P., & Zhang, Z. (2026). Glucose/ROS dual-responsive mitochondria-targeting nanozyme microneedles remodel mitochondrial homeostasis to orchestrate immune metabolic reprogramming for diabetic foot ulcer healing. Regenerative Biomaterials, 13. https://doi.org/10.1093/rb/rbag153
Vancouver
Dong Q, Xiong S, Shu B, Cai Z, Wang S, Ming Y, et al. Glucose/ROS dual-responsive mitochondria-targeting nanozyme microneedles remodel mitochondrial homeostasis to orchestrate immune metabolic reprogramming for diabetic foot ulcer healing. Regenerative Biomaterials. 2026;13. doi:10.1093/rb/rbag153
BibTeX
@article{Dong2026,
author = {Dong, Qi and Xiong, Siyu and Shu, Bing and Cai, Zhiwei and Wang, Shangqing and Ming, Yang and Dong, Xiongwei and Chen, Peng and Zhang, Zhaowei},
title = {Glucose/ROS dual-responsive mitochondria-targeting nanozyme microneedles remodel mitochondrial homeostasis to orchestrate immune metabolic reprogramming for diabetic foot ulcer healing},
journal = {Regenerative Biomaterials},
year = {2026},
volume = {13},
doi = {10.1093/rb/rbag153}
}
EUVIMED